Pemphigus Vulgaris Market is expected to grow USD 4.26 Million at a CAGR 9.10% during the forcast period 2023 to 2030.Pemphigus Vulgaris is a type of autoimmune disease in which the antibodies produced against the bacteria attack the healthy cells and causes skin problems. Pemphigus Vulgaris affects both men and women, but middle- and old-aged people are more likely to develop this condition.
Market Dynamics
The key factors responsible for influencing the market growth are the increasing prevalence of pemphigus vulgaris, rising bacterial and viral infection, and the growing prevalence of cancer. The side effects associated with the medication and increase in geriatric population are also estimated to drive the market during the forecast period. However, factors such as high cost related to treatment, unfavorable reimbursement situation, and lack of awareness are expected to restrain the market growth
Pemphigus vulgaris is one of the most life-threatening autoimmune skin disorders that occurs due to various reasons such as bacterial infection, increasing pollution, and side effects of some medications. According to the National Organization for Rare Disorders (NORD), 2015, the prevalence of pemphigus was high within the US and Europe affecting approximately 0.7 to 5 people per 1,000,000 each year in the overall population. It was also mentioned that pemphigus foliaceus a form of pemphigus vulgaris has a high prevalence in Africa and some rural areas in the world.
According to the International Pemphigus & Pemphigoid Foundation, it was predicted that approximately 40,000 to 50,000 people across the world and 2,500 people in the US were diagnosed with pemphigus disorder in 2017. The increase in the prevalence of pemphigus vulgaris across the globe is expected to drive market growth during the forecast period from 2023 to 2030.
Global Pemphigus Vulgaris Market Share, by Type, 2017 (%) 
Source: MRFR Analysis
Segmentation
The global pemphigus vulgaris market, by treatment, has been segmented into corticosteroids, immunosuppressants, biological therapies, and intravenous immunoglobulin (IVIG) therapy. Based on the route of administration, the market has been classified as intravenous, subcutaneous, and oral. By end user, the global pemphigus vulgaris market has been categorized as hospitals & clinics, specialty dermatology clinics, and research & academic laboratories.
Global Pemphigus Vulgaris Market Share, by Region, 2017 (%) 
Source: MRFR Analysis
Regional Analysis
The global pemphigus vulgaris market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
The Americas accounted for the largest market share in 2030 and is estimated to dominate the global pemphigus vulgaris market. The Americas is anticipated to reach USD 426 million by 2030 at a CAGR of 9.10% from 2023 to 2030. The Americas accounts for the largest regional market owing to the increasing prevalence of pemphigus vulgaris, increasing geriatric population, and raising funding for the research & development of skin diseases. According to the National Center for Biotechnology Information 2014, it was predicted that the prevalence of pemphigus vulgaris in the US is in the range of 0.76 to 5 new cases per million every year. Also, according to the International Pemphigus & Pemphigoid Foundation, it was projected that approximately 2,500 people in the US suffered from pemphigus disorder in 2017.
Europe accounted for the second-largest market share in 2017 due to extensive R&D for pemphigus vulgaris, increasing funding, and growing adoption of the technology within the region. Asia-Pacific is expected to contribute to the market growth for pemphigus vulgaris during the forecast period owing to rising therapeutic demand for pemphigus vulgaris and rapidly evolving healthcare sector. On the other hand, the Middle East & Africa is expected to observe slow growth due to low per capita disposable incomes, lack of awareness, and less exposure to healthcare services in this region.
Key Players
The prominent players in the global pemphigus vulgaris market are Almirall, SA, Argenx SE, Biogen Inc., F. Hoffmann-La Roche, Syntimmune, Pfizer Inc., Novartis AG, Sanofi, Janssen Global Services, LLC, and Principia Biopharma.
Some of the key strategies followed by players operating in the global pemphigus vulgaris market were innovation, product development, and acquisition & mergers.
- In December 2017, Almirall SA and Athenex entered into a strategic partnership to develop and commercialize KX2-391 in the US and Europe for the treatment of actinic keratosis.
- In January 2018, Pandion Therapeutics, a start-up led by former executives at Pfizer and Biogen, attracted USD 58 million in financing for the development of a new class of drugs that could tweak the immune system without triggering significant side effects.
- In February 2018, Roche announced that the US Food and Drug Administration (FDA) had accepted the company’s supplemental biologics license application (SBLA) and granted priority review for the use of MabThera/Rituxan (Rituximab) for the treatment of pemphigus vulgaris (PV), a rare, life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes.
Market Segmentation
Global Pemphigus Vulgaris Market, by Treatment
- Corticosteroids
- Immunosuppressants
- Biological Therapies
- Intravenous Immunoglobulin (IVIG) Therapy
Global Pemphigus Vulgaris Market, by Route of Administration
- Intravenous
- Subcutaneous
- Oral
Global Pemphigus Vulgaris Market, by End User
- Hospitals & Clinics
- Specialty Dermatology Clinics
- Research & Academic Laboratories
Global Pemphigus Vulgaris Market, by Region
- Europe
- Western America
- Germany
- France
- UK
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Asia-Pacific
- China
- Japan
- Australia
- Republic of Korea
- India
- Rest of Asia-Pacific
Available Additional Customizations
- Treatment cost analysis
- Epidemiology data
- Clinical trials data
Intended Audience
- Clinical laboratories
- Pharmaceutical market
- Government organizations
- Research & consulting firms
- Biotechnology companies
| Report Attribute/Metric |
Details |
| Market Size |
4.26 Million |
| CAGR |
9.10% |
| Base Year |
2022 |
| Forecast Period |
2023-2030 |
| Historical Data |
2021 |
| Forecast Units |
Value (USD Million) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Treatment, Route of Administration, End User and Region |
| Geographies Covered |
North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors |
Almirall, SA, Argenx SE, Biogen Inc., F. Hoffmann-La Roche, Syntimmune, Pfizer Inc., Novartis AG, Sanofi, Janssen Global Services, LLC, and Principia Biopharma |
| Key Market Opportunities |
Advancements In Treatments |
| Key Market Drivers |
Increasing Prevalence Of Pemphigus Vulgaris Globally Growing Financial Support By Various Private And Government Organizations For Research Of Diseases Increasing Geriatric Population |
Pemphigus Vulgaris Market Highlights:
Frequently Asked Questions (FAQ) :
Pemphigus vulgaris market projected to grow at approximately 9.10% CAGR during the assessment period (2023-2030).
The valuation of the global pemphigus vulgaris market is estimated to increase to USD 4.26 Million by the end of 2030.
Rising prevalence and higher awareness regarding the disease and advancements in diagnosis & treatment process are major tailwinds pushing the growth of the global pemphigus vulgaris market.
North America holds the largest share in the global pemphigus vulgaris market, followed by Europe and the Asia Pacific, respectively.
Janssen Global Services LLC (U.S.), Syntimmune (India), Argenx SE (Belgium), Novartis AG (Switzerland), Sanofi (France), Pfizer Inc. (U.S.), Biogen Inc. (U.S.), Almirall SA (Spain), Principia Biopharma (U.S.), and F. Hoffman-La Roche (Switzerland), are some of the top players operating in the global pemphigus vulgaris market.
